Kannabinoid Reseptör Antagonistleri AM251 ve AM630’un Anestezi Altındaki Sıçanlarda İskemi/Reperfüzyon ile Uyarılan Aritmiler Üzerine Etkileri
Amaç: Bu çalışmanın amacı AM251(kannabinoid-1 reseptör antagonisti) ve AM630’un (kannabinoid-2 reseptör antagonisti) anestezi
altındaki sıçanlarda iskemi/reperfüzyon (I/R) ile uyarılan aritmiler üzerine etkilerini araştırmaktır.
Gereç ve Yöntemler: Wistar Albino türü erkek sıçanlar 3 gruba ayrıldı: I) Kontrol (n=13), II) AM251 (n=17) ve III) AM630 (n=17).
AM251 ve AM630 1mg/kg dozda intravenöz yolla ligasyondan 10 dakika önce verildi. Üretan ile anestezi edilen sıçanlarda sol ana
koroner arter bağlanarak 6 dakika iskemi, tıkanan damar gevşetilerek 10 dakika reperfüzyon yapıldı. Tüm gruplardaki deneklerde iskemi
ve reperfüzyon periyotlarında ventriküler aritmi süreleri, EKG’de QRS, Q-T ve P-R aralıkları, kalp atımı ve ortalama arteriyal kan basıncı
hesaplandı.
Bulgular: AM251 reperfüzyon periyodunda ölüm oranını, ventriküler taşikardi ve ventriküler fibrilasyonun görülme sıklığını,
ventriküler fibrilasyon süresi, toplam aritmi süresi ve aritmi skorunu kontrol grubuna göre istatistiksel olarak anlamlı bir şekilde artırdı
(p<0.05).
Sonuç: Kannabinoid-1 reseptör antagonisti AM251 I/R ile uyarılan aritmileri arttırdı. Kannabinoid-2 reseptör antagonisti AM630 ise
herhangi bir etki göstermedi. Bu sonuçlar endojen kannabinoidlerin KB1 reseptör aktivasyonu yoluyla ventriküler aritmilerin oluşumunu
azaltıcı bir role sahip olabileceğini göstermektedir.
The Effects of Cannabinoid Receptor Antagonists AM251 and AM630 on Ischemia/Reperfusion-Induced Arrhythmias in Anesthetized Rats
Aim: The aim of this study is to investigate the effects of AM251 (cannabinoid-1 receptor antagonist) and AM630 (cannabinoid-2
receptor antagonist) on ischemia/reperfusion (I/R)-induced arrhythmias in anesthetized rats.
Materials and Methods: Wistar Albino male rats were divided into 3 groups: I) Control (n = 13), II) AM251 (n = 17) and III) AM630
(n = 17). AM251 and AM630 were administered intravenously at 1 mg / kg dose 10 minutes prior to ligation. In the anesthetized rats
with urethan, the left main coronary artery was ligated to perform the ischemia for 6 minutes, the occluded artery was loosened and
reperfusion was performed for 10 minutes.Ventricular arrhythmia durations, QRS, Q-T and P-R intervals in ECG recordings, heart rate
and mean arterial blood pressure were calculated in ischemia and reperfusion period in all in all groups of rats.
Results: The AM251 significantly increased mortality, the incidence of ventricular tachycardia and ventricular fibrillation, the duration
of total arrhythmia and the ventricular fibrillation and the arrhythmia scores compared to the control group (p<0.05).
Conclusion: The cannabinoid-1 receptor antagonist AM251 increased I/R-induced arrhythmias. The cannabinoid-2 receptor antagonist
AM630 did not show any effect. These results demonstrate that endogenous cannabinoids may have a role in the reducing the generatiom
of ventricular arrhythmias via KB1 receptor activation.
___
- 1. Ferrari R, et al. Reperfusion damage- a story of success, failure,
and hope. Circ J. 2017;81(2):131-141.
- 2. Gonca E, et al. Cardioprotective effect of zileuton: A
5-lipoxygenase inhibitor against myocardial ischemia/
reperfusion injury. Turkish Journal of Thoracic and
Cardiovascular Surgery. 2017;25(2):273-281.
- 3. Gonca E. The effects of zileuton and montelukast in
reperfusion-induced arrhythmias in anesthetized rats. Curr
Ther Res Clin Exp. 2013;75:27-32.
- 4. Howlett AC, et al. Cannabinoid physiology and pharmacology:
30 years of progress. Neuropharmacology. 2004;47:345–358.
- 5. Ben Amar M. Cannabinoids in medicine: A review of their
therapeutic potential. J Ethnopharmacol. 2006;105(1-2):1-25.
- 6. Bisogno T, et al. Molecular targets for cannabidiol and its
synthetic analogues: Effect on vanilloid VR1 receptors and on
the cellular uptake and enzymatic hydrolysis of anandamide.
British Journal of Pharmacology. 2001;134(4):845-852.
- 7. Gebremedhin D, et al. Cannabinoid CB1 receptor of cat cerebral
arterial muscle functions to inhibit L-type Ca2+channel
current. The American Journal Physiology. 1999;276:2085-
2093.
- 8. Liu J, et al. Functional CB1 cannabinoid receptors in
human vascular endothelial cells. The Biochemical Journal.
2000;346:835-840.
- 9. Di Marzo V. The endocannabinoid system: Its general strategy
of action, tools for its pharmacological manipulation and
potential therapeutic exploitation. Pharmacological Research.
2009;60(2):77-84.
- 10. Walsh SK, et al. Pharmacological profiling of the hemodynamic
effects of cannabinoid ligands: A combined in vitro and in vivo
approac. Pharmacol Research Perspect. 2015;3(3):1-17.
- 11. Cunha P, et al. Endocannabinoid system in cardiovascular
disorders - new pharmacotherapeutic opportunities. Journal
of Pharmacy& Bioallied Science. 2011;3(3):350-360.
- 12. Wagner JA, et al. CB(1) cannabinoid receptor antagonism
promotes remodelling and cannabinoid treatment prevents
endothelial dysfunction and hypotension in rats with
myocardial infarction. British Journal Pharmacology.
2003;138:1251-1258.
- 13. Batkai S, et al. Cannabinoid antagonist SR-141716 inhibits
endotoxic hypotension by a cardiac mechanism not involving
CB1 or CB2 receptors. American Journal of Physiology. Heart
and Circulatory Physiology. 2004;287(2):595–600.
- 14. Hepburn CY, et al. Cannabidiol as an antiarrhythmic, the role
of the CB1 receptors. Heart. 2011;97(24):8.
- 15. Andrag E, Curtis MJ. Feasibility of targeting ischemia-related
ventricular arrhythmias by mimicry of endogenous protection
by endocannabinoids. British Journal of Pharmacology.
2013;169(8):1840-1848.
- 16. Hajrasouliha AR, et al. Endogenous cannabinoids contribute
to remote ischemic preconditioning via cannabinoid CB2
receptors in the rat heart. European Journal of Pharmacology.
2007;579: 246-252.
- 17. Hosohata K, et al. AM630 is a competitive cannabinoid
receptor antagonist in the guinea pig brain. Life Sciences.
1997;61(9):115-118.
- 18. Lan R, et al. Structure-activity relationships of pyrazole
derivatives as cannabinoid receptor antagonists. Journal of
Medicinal Chemistry. 1999;42:769-776.
- 19. Curtis MJ, et al. The Lambeth Conventions (II): Guidelines for
the study of animal and human ventricular and supraventricular
arrhythmias. Pharmacology&Therapeutics. 2013;139(2):213-
248.
- 20. Lepran I, et al. Coronary artery ligation, early arrhythmias, and
determination of the ischemic area in conscious rats. Journal
Pharmacological Methods. 1983;9(3):219-230.
- 21. Bazett HC. An analysis of the time relationships of
electrocardiograms. Annals of Noninvasive Electrocardiology.
2006;2(2):177-194.
- 22. Gulcu-Bulut N, et al. Pretreatment with stellate ganglion
blockade before ischemia reduces infarct size in rat hearts.
Saudi Medical Journal. 2010;31(2):148-152.
- 23. Rudz R, et al. Acute myocardial infarction inhibits the
neurogenic tachycardic and vasopressor response in rats via
presynaptic cannabinoid type 1 receptor. Journal Pharmacol
Experimental Therapeutics. 2012;343:198-205.
- 24. Faber GM, Rudy Y. Calsequestrin mutation and catecholaminergic
polymorphic ventricular tachycardia: A simulation
study of cellular mechanism. Cardiovasc Research.
2007;75(1):79-88.
- 25. Oka S, et al. Identification of GPR55 as a lysophosphatidylinositol
receptor. Biochem Biophys Res Commun 2007;362:928-934.
- 26. Robertson-Gray OJ, et al. Exogenous lysophosphatidolinositol
exacerbates myocardial tissue ınjury via a GPR55 dependent
mechanism. Heart. 2014;100(4).
- 27. Ryberg E, et al. The orphan receptor GPR55 is a novel
cannabinoid receptor. British Journal of Pharmacology.
2007;152(7):1092-2101.
- 28. Kalogeris T, et al. Cell biology of ischemia/reperfusion injury.
Int Rev Cell Mol Biol. 2012;298:229-317.
- 29. Pogwizd SM, Corr PB. Electrophysiologic mechanisms underlying
arrhythmias due to reperfusion of ischemic myocardium.
Circulation. 1987;76(2):404-426.
- 30. Gonca E, Darici F. The effect of cannabidiol on ischemia/
reperfusion-induced ventricular arrhythmias: The role
of adenosine A1 receptors. Journal of Cardiovascular
Pharmacology and Therapeutics. 2014;20(1):76-83.
- 31. Krylatov AV, et al. Activation of type II cannabinoid receptors
improves myocardial tolerance to arrhythmogenic effects of
coronary occlusion and reperfusion. Bulletin of Experimental
Biology and Medicine. 2001;131(6):523-525.
- 32. Lepicier P, et al. Endothelial CB1-receptors limit infarct size
through NO formation in rat isolated hearts. Life Science.
2007;81:1373-1380.
- 33. Qian Li, et al. Electrophysiological effects of anandamide
on rat myocardium. Brithis Journal Pharmacology.
2009;158(8):2022–2029.
- 34. Farkas A, et al. Inadequate ischaemia-selectivity limits
the antiarrhythmic efficacy of mibefradil during regional
ischaemia and reperfusion in the rat isolated perfused heart.
Br J Pharmacol. 1999;128(1):41-50.
- 35. Rees SA, Curtis MJ. Pharmacological analysis in rat of the role
of the ATP-sensitive potassium channel as a potential target for
antifibrillatory intervention in acute myocardial ischaemia. J
Cardiovasc Pharmacol. 1995;26:280-288.
- 36. Rees SA, Curtis MJ. Which cardiac potassium channel
subtype is the preferable target for suppression of ventricular
arrhythmias? Pharmacol Ther. 1996;69:199-217.
- 37. Tamargo J, et al. Pharmacology of cardiac potassium channels.
Cardiovasc Research. 2004;62(1):9-33.
- 38. Tsuchihashi K, Curtis MJ. Influence of tedisamil on the
initiation and maintenance of ventricular fibrillation: Chemical
defibrillation by Ito blockade? J Cardiovasc Pharmacol.
1991;18:445-456.
- 39. Wagner JA, et al. Hemodynamic effects of cannabinoids:
Coronary and cerebral vasodilatation mediated by cannabinoid
CB1 receptors. European Journal Pharmacol. 2001;423:203-
210.
- 40. Pacher P, et al. Blood pressure regulation by endocannabinoids
and their receptors. Neuropharmacology. 2005;48(8):1130-
1138.